Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
J Clin Periodontol ; 34(8): 658-67, 2007 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-17635245

RESUMEN

OBJECTIVE: To compare the effects of an experimental mouth rinse containing 0.07% cetylpyridinium chloride (CPC) (Crest Pro-Health) with those provided by a commercially available mouth rinse containing essential oils (EOs) (Listerine) on dental plaque accumulation and prevention of gingivitis in an unsupervised 6-month randomized clinical trial. MATERIAL AND METHODS: This double-blind, 6-month, parallel group, positively controlled study involved 151 subjects balanced and randomly assigned to either positive control (EO) or experimental (CPC) mouth rinse treatment groups. At baseline, subjects received a dental prophylaxis procedure and began unsupervised rinsing twice a day with 20 ml of their assigned mouthwash for 30 s after brushing their teeth for 1 min. Subjects were assessed for gingivitis and gingival bleeding by the Gingival index (GI) of Löe & Silness (1963) and plaque by the Silness & Löe (1964) Plaque index at baseline and after 3 and 6 months of rinsing. At 3 and 6 months, oral soft tissue health was assessed. Microbiological samples were also taken for community profiling by the DNA checkerboard method. RESULTS: Results show that after 3 and 6 months of rinsing, there were no significant differences (p=0.05) between the experimental (CPC) and the positive control mouth rinse treatment groups for overall gingivitis status, gingival bleeding, and plaque accumulation. At 6 months, the covariant (baseline) adjusted mean GI and bleeding sites percentages for the CPC and the EO rinses were 0.52 and 0.53 and 8.7 and 9.3, respectively. Both mouth rinses were well tolerated by the subjects. Microbiological community profiles were similar for the two treatment groups. Statistically, a significant greater reduction in bleeding sites was observed for the CPC rinse versus the EO rinse. CONCLUSION: The essential findings of this study indicated that there was no statistically significant difference in the anti-plaque and anti-gingivitis benefits between the experimental CPC mouth rinse and the positive control EO mouth rinse over a 6-month period.


Asunto(s)
Antiinfecciosos Locales/uso terapéutico , Cetilpiridinio/uso terapéutico , Placa Dental/tratamiento farmacológico , Gingivitis/tratamiento farmacológico , Antisépticos Bucales/uso terapéutico , Aceites Volátiles/uso terapéutico , Adolescente , Adulto , Placa Dental/microbiología , Métodos Epidemiológicos , Femenino , Gingivitis/prevención & control , Humanos , Masculino , Persona de Mediana Edad
2.
Curr Opin Periodontol ; 4: 51-8, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9655021

RESUMEN

For the past three decades, prostaglandin E2 and other arachidonic acid metabolites have been recognized as important proinflammatory mediators in bone resorption and various forms of periodontal disease. Nonsteroidal anti-inflammatory drugs are chemical compounds that selectively inhibit the synthesis of metabolites of the cyclooxygenase pathway, thereby blocking the production of prostaglandins, thromboxane, and prostacyclin. Inhibiting prostaglandin E2 synthesis with nonsteroidal anti-inflammatory drugs has been unequivocally shown in both animal and human studies to be of primary therapeutic efficacy. Recent lines of nonsteroidal anti-inflammatory drugs research have focused on the development of daily topical administration forms such as gels, toothpastes, and rinses. Furthermore, new studies have implicated prostaglandin E2 in the peri-implantitis process, opening the possibility to manage failing implants with topical nonsteroidal anti-inflammatory drug delivery systems.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Enfermedades Periodontales/tratamiento farmacológico , Antagonistas de Prostaglandina/uso terapéutico , Administración Tópica , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Quimioterapia Adyuvante , Implantes Dentales/efectos adversos , Progresión de la Enfermedad , Humanos , Enfermedades Periodontales/metabolismo , Periodontitis/tratamiento farmacológico , Periodontitis/etiología , Antagonistas de Prostaglandina/administración & dosificación , Prostaglandinas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA